Clinical Trials Logo

Filter by:
NCT ID: NCT02476864 Completed - Healthy Subjects Clinical Trials

Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults

Start date: August 2015
Phase: Phase 1
Study type: Interventional

A study conducted in healthy adults to investigate if a new macitentan tablet leads to the same fate of macitentan in the body (time of onset, time of presence, amount in the blood) as the marketed macitentan tablet.

NCT ID: NCT02465814 Completed - Leiomyoma Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

ASTEROID 2
Start date: June 2015
Phase: Phase 2
Study type: Interventional

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.

NCT ID: NCT02447757 Completed - Clinical trials for Complication of Labor and/or Delivery

Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth

Start date: January 2010
Phase: N/A
Study type: Observational

Retrospective observational study to determine the efficacy of remifentanil during the delivery. Authors will search the data in period between 2010 and 2014 in cohort of 100 parturients and obtain data of analgesic efficacy (VAS score after remifentanil analgesia induction) and parturients satisfaction with the method.

NCT ID: NCT02433366 Completed - Atrial Fibrillation Clinical Trials

Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation

Start date: January 2015
Phase: N/A
Study type: Observational

The key focus of this survey will be to collect data on physicians awareness of the content of the Pradaxa® Prescriber Guide and the extent to which risk awareness is communicated to patients. The data collected with atrial fibrillation patients will show if and how well this information is received and understood.

NCT ID: NCT02433340 Completed - Clinical trials for Rheumatoid Arthritis

Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

Start date: April 2015
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, 24-week, open-label extension (OLE) study to assess the safety and tolerability of ABT-122 in rheumatoid arthritis (RA) subjects who have completed Study M12-963 Phase 2 RCT.

NCT ID: NCT02431741 Completed - Malignant Wounds Clinical Trials

A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds

Start date: October 2014
Phase: N/A
Study type: Interventional

This is a prospective, open, non-controlled clinical investigation to evaluate the performance and safety of using Mepilex Transfer Ag on a malignant wound. Approximately ten to fifteen (10-15) subjects from one to three centers in Europe, presenting with a malignant (fungating) wound will be enrolled into the study. Eligible subjects will have one malignant (fungating) wound selected as a "study site". Subjects will be followed for a one-week observation period with their existing product followed by a 4-week investigation period using Mepilex Transfer Ag.

NCT ID: NCT02430532 Terminated - Clinical trials for Multiple Sclerosis, Secondary Progressive

BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)

INSPIRE
Start date: May 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with SPMS; The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.

NCT ID: NCT02429895 Terminated - Psoriatic Arthritis Clinical Trials

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Start date: October 2015
Phase: Phase 2
Study type: Interventional

A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT).

NCT ID: NCT02428231 Terminated - Multiple Sclerosis Clinical Trials

Tecfidera Slow-titration Study

TITRATION
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF)-related gastrointestinal (GI) Adverse Events (AEs) in subjects with Multiple Sclerosis (MS). The secondary objective of this study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the average severity and duration of GI symptoms over 12 weeks of dimethyl fumarate treatment in this study population.

NCT ID: NCT02417129 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Start date: April 2015
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-blind, parallel-arm, active comparator trial to evaluate BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with LTBFL. Patients will be randomly assigned in a 1:1 ratio to receive 375 mg/m2 of BI 695500 or rituximab via intravenous (IV) infusion once a week for 4 weeks (total of 4 dosages administered on Days 1, 8, 15, and 22). Disease assessments will be performed at the End of Study (EOS) Visit at Week 30.